Genetic predisposition and induced pro-inflammatory/prooxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients

Oncotarget

Volumn 7, Issue 44, 2016, Pages 72311-72321

  Bocchia, Monica ^a   Galimberti, Sara ^b   Aprile, Lara ^a   Sicuranza, Anna ^a   Gozzini, Antonella ^c   Santilli, Francesca ^d   Abruzzese, Elisabetta ^e   Baratè, Claudia ^b   Scappini, Barbara ^c   Fontanelli, Giulia ^b   Trawinska, Monika Malgorzata ^e   Defina, Marzia ^a   Gozzetti, Alessandro ^a   Bosi, Alberto ^c   Petrini, Mario ^b   Puccetti, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Atherothrombotic risk; CML; Inflammation; PAOD; TKI

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 6; NILOTINIB; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; THROMBIN; TUMOR NECROSIS FACTOR; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; CYTOKINE; OLR1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER PATIENT; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOGENETICS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOGENOUS THROMBIN POTENTIAL; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEMATOLOGICAL PARAMETERS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ORL1 GENE; OXIDATIVE STRESS; RETROSPECTIVE STUDY; THROMBOSIS; TREATMENT DURATION; ATHEROSCLEROSIS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; INCIDENCE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; CYTOKINES; DYSLIPIDEMIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMATINIB MESYLATE; INCIDENCE; INFLAMMATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; SCAVENGER RECEPTORS, CLASS E; THROMBOSIS;

EID: 84995449864     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11100     Document Type: Article

References (43)

1. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123-32
2. Breccia M, Colafigli G, Molica M, Alimena G. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Expert Opin Drug Saf. 2016; 16:1-9
3. Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016;11:71-9
4. Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90:66-72
5. Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2015; 20:1-11
6. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33:4210-8
7. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9
8. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dörken B, Valent P. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347-8
9. Le Coutre P, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Wallis N and Cortes J. Arterial occlusive disease (PAOD) in patients (Pts) receiving dasatinib: experience across multiple clinical trials. Blood ASH annual meeting abstract 2013;122:1489
10. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-5
11. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, Labussière H, Lindhorst R, Haverkamp W, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27:1316-21
12. Gora-Tybor J, Medras E, Calbecka M, Kolkowska-Lesniak A, Ponikowska-Szyba E, Robak T, Jamroziak K. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma. 2015;5:1-6
13. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015; 125 :901-6
14. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Grebien F, Eisenwort G, Schgoer W, Kaun C, Herndlhofer S, Theurl M, Cerny-Reiterer S, Hoermann G, Sperr WR, Rix U. Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. Blood 2014; 124 (abstract 1800)
15. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinibassociated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337-40
16. Hekmatjou H, Roboz GJ, Ritchie EK, Lee S, Desai P, Scandura JM, Allen-Bard S, Christos P, Silver RT, Feldman EJ. Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. Blood 2014; 124 (abstract 1811)
17. Gilbert J, Deplano S, Szydlo R, Palanicawandar R, Gerrard G, Foroni L, Apperley JF, Milojkovic D. Incidence of Vascular Thrombotic Events in 183 Consecutive Patients Treated with Nilotinib: A Single Centre Experience. Blood 2014; 124 (abstract 3147)
18. Breccia M1, Molica M, Zacheo I, Serrao A, Alimena G. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol. 2015; 94:393-7
19. Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016;11:549-52
20. Mirault T, Rea D, Azarine A, Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. Eur J Haematol. 2015;94:363-7
21. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-51
22. Wolf D, Stachon P, Bode C, Zirlik A. Inflammatory mechanisms in atherosclerosis. Hamostaseologie 2014;34:63-71
23. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, Sawamura T. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther 2011;25:495-500
24. Predazzi IM, Martinez-Labarga C, Vecchione L, Mango R, Ciccacci C, Amati F, Ottoni C, Crawford MH, Rickards O, Romeo F, Novelli G. Population differences in allele frequencies at the OLR1 locus may suggest geographic disparities in cardiovascular risk events. Ann Hum Biol 2010;37:137-49
25. Lubrano V, Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res. 2016;18,30012-7
26. Emerging Risk Factors Collaboration Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20
27. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008;54:2042-8
28. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 2010;43:666-70
29. Tefferi A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? Leukemia. 2013;27:1939-40
30. Mango R, Predazzi IM, Romeo F, Novelli G. LOX-1/LOXIN: the yin/yang of atheroscleorosis. Cardiovasc Drug Ther 2011;25:489-94
31. Linna M, Ahotupa M, Löppönen MK, Irjala K, Vasankari T. Circulating oxidised LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study. Age Ageing 2013;42:110-3
32. Gómez M, Vila J, Elosua R, Molina L, Bruguera J, Sala J, Masià R, Covas MI, Marrugat J, Fitó M. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. Atherosclerosis 2014;232:134-40
33. Santilli F, Basili S, Ferroni P, Davì G. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007;2:256-68
34. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008;79:360-76
35. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial Eur Heart J 2012;33:486-94
36. Blake GJ, Ridker, PM. C-reactive protein: A surrogate risk marker or mediator of atherothrombosis? Am J Physiol Regul Integr Comp Physiol. 2003;285:R1250-2
37. Violi F, Pignatelli P. Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review. Antioxid Redox Signal. 2015;23:514-32
38. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217 Suppl 1:S1-44
39. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith Jr SC, Levy D, Watson K, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2015;23:514-32
40. Arjuman A, Chandra NC. Effect of IL-10 on LOX-1 expression, signaling and functional activity: an atheroprotective response. Diab Vasc Dis Res 2013;10:442-51
41. Gorga E, Vizzardi E, Bonadei I, Piovanelli B, Della Pina P, Raddino R, Dei Cas L. LOX-1 and its implications on cardiovascular diseases a possible new perspective target on atherosclerosis. J Clin Exp Cardiol 2013;4:1
42. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329-40
43. Achterberg S, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FL, van der Graaf Y, Algra A; SMART study Group. Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev Rehabil 2010;17:424-30